

# A model of anthrax toxin lethal factor bound to protective antigen

D. Borden Lacy\*, Henry C. Lin\*, Roman A. Melnyk\*, Ora Schueler-Furman<sup>†</sup>, Laura Reither<sup>‡</sup>, Kristina Cunningham\*<sup>§</sup>, David Baker<sup>†¶</sup>, and R. John Collier\*<sup>||</sup>

\*Department of Microbiology and Molecular Genetics and <sup>‡</sup>Graduate Group of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, 200 Longwood Avenue, Boston, MA 02115; and <sup>†</sup>Department of Biochemistry and <sup>¶</sup>Howard Hughes Medical Institute, University of Washington, Seattle, WA 98195

Contributed by R. John Collier, September 21, 2005

**Anthrax toxin is made up of three proteins: the edema factor (EF), lethal factor (LF) enzymes, and the multifunctional protective antigen (PA). Proteolytically activated PA heptamerizes, binds the EF/LF enzymes, and forms a pore that allows for EF/LF passage into host cells. Using directed mutagenesis, we identified three LF-PA contact points defined by a specific disulfide crosslink and two pairs of complementary charge-reversal mutations. These contact points were consistent with the lowest energy LF-PA complex found by using Rosetta protein-protein docking. These results illustrate how biochemical and computational methods can be combined to produce reliable models of large complexes. The model shows that EF and LF bind through a highly electrostatic interface, with their flexible N-terminal region positioned at the entrance of the heptameric PA pore and thus poised to initiate translocation in an N- to C-terminal direction.**

computation | docking | electrostatic

**B***acillus anthracis*, the causative agent of anthrax, secretes three monomeric proteins, protective antigen (PA), edema factor (EF), and lethal factor (LF), that are collectively referred to as anthrax toxin (1). After its proteolytic activation and assembly into oligomeric complexes, PA can mediate the delivery of the two catalytic factors, EF and LF, into the host cell cytosol, where they can access their substrates. EF, an 89-kDa calmodulin-dependent adenylate cyclase, elevates levels of cAMP (2). LF, named for its lethal effect in animals, is a 90-kDa zinc protease that has been shown to cleave and inactivate mitogen-activated protein kinase-kinases (3, 4).

The current model for intoxication involves a multistep mechanism, the first step being binding of the 83-kDa PA monomer (PA<sub>83</sub>) to a host-cell surface receptor (1). Binding is followed by proteolytic cleavage of PA<sub>83</sub>, resulting in the removal of a 20-kDa fragment (PA<sub>20</sub>) from the N terminus (5). The remaining 63-kDa PA (PA<sub>63</sub>) is then able to oligomerize, forming a heptameric, soluble prepore (6), which, in turn, binds a maximum of three molecules of EF and/or LF (7). The limit of three has been proposed to derive from EF and LF having a footprint of binding that encompasses two PA<sub>63</sub> subunits (8). The entire complex of the (PA<sub>63</sub>)<sub>7</sub> prepore and bound catalytic factor(s) is internalized into an endosome by receptor-mediated endocytosis (9). The increasing acidity of the endosome causes a conformational change in the prepore assembly, allowing it to penetrate the endosomal membrane and form a pore (1). This pore is thought to allow for the translocation of fully or partially unfolded EF or LF through the endosomal membrane into the cytosol, where catalysis can occur (10, 11).

EF and LF have entirely different catalytic activities but share at their N termini a common domain with significant sequence and structural homology (12, 13). This domain, referred to as EF<sub>N</sub> or LF<sub>N</sub>, contains the site that allows EF and LF to bind PA competitively and with high affinity ( $K_d \approx 1$  nM) (14). EF<sub>N</sub> and LF<sub>N</sub> share a cluster of seven conserved amino acids that were shown by site-directed mutagenesis and a cell-surface binding

assay to be important for binding PA (15). These residues form a relatively flat surface with dimensions of  $\approx 10$ – $15$  Å (Fig. 1*a*). Two of the seven amino acids are Asp residues and are likely to give the binding site a net negative charge.

Binding of EF/LF depends on and potentially drives the oligomerization of PA<sub>63</sub> (16). This interaction was discovered through the use of two oligomerization-deficient forms of PA, each mutated on a different PA<sub>63</sub>–PA<sub>63</sub> contact face. Neither form of PA alone is able to oligomerize or bind ligand, either in solution or on cells. However, when the two mutant forms of PA are combined, there is one wild-type interface that allows for dimer formation in the presence of ligand. The discovery that stable PA<sub>63</sub>–PA<sub>63</sub> dimers formed only in the presence of ligand led to the hypothesis that the EF/LF-binding site spanned two PA<sub>63</sub> subunits. Mutations were introduced into each of the two oligomerization-deficient forms of PA to map the single ligand-binding site within dimeric PA (8). The results suggested that the EF/LF-binding site was formed by two clusters of residues separated by  $\approx 30$  Å in the PA dimer (Fig. 1*b*). The two clusters are located on a relatively flat surface and are positively charged, because combined they contain three Arg and three Lys residues.

In this study, we docked LF<sub>N</sub> across a PA-dimer interface in two distinct orientations and evaluated these models computationally by using only their computed energies. Independently, we explored the binding by directed mutagenesis. Cys-scanning mutagenesis revealed a site where a specific disulfide crosslink can form between bound LF<sub>N</sub> and PA, and we also found two pairs of electrostatic interactions by charge-reversal mutagenesis. The three contact points identified by the mutational analysis define a single orientation of LF<sub>N</sub>, and this orientation coincides with the lowest energy model that emerged from the computational analysis. The binding orientation yields insights into the subsequent steps of the entry process of LF and EF, including their unfolding and translocation through the PA pore.

## Materials and Methods

**Modeling the Structure of the LF<sub>N</sub>–PA Dimer Complex.** To reduce computational time, the PA<sub>63</sub>–PA<sub>63</sub> dimer was truncated to include residues 177–260 (the subdomain that contains the EF/LF-binding site) and 458–595 (a subdomain that mediates oligomerization). The manually docked models were used as a starting point for sampling the surrounding free energy landscape by using many independent Monte Carlo minimization trajectories according to a Rosetta-Dock protocol described in refs. 17 and 18. Briefly, the rigid degrees of freedom of the starting model are randomly perturbed, and the perturbed model

Conflict of interest statement: R.J.C. holds equity in PharmAthene, Inc., a company engaged in developing countermeasures to biothreat agents, including *Bacillus anthracis*.

Abbreviations: EF, edema factor; LF, lethal factor; PA, protective antigen; rmsd, rms deviation.

<sup>§</sup>Present address: Wyeth Research, Cambridge, MA 02140.

<sup>||</sup>To whom correspondence should be addressed. E-mail: john.collier@hms.harvard.edu.

© 2005 by The National Academy of Sciences of the USA









partner protein and reasoned that pairing these charge-reversal mutants so that they could maintain an electrostatic interaction might rescue binding for these otherwise defective mutants. We identified two such pairs of charge-reversal mutants: LF<sub>N</sub> D187K-PA K213D/K213E and LF<sub>N</sub> E142K-PA K218E, suggesting that the LF<sub>N</sub> D187-PA K213 and LF<sub>N</sub> E142-PA K218 residues are close in the LF<sub>N</sub>-PA complex (Fig. 4). In the low-energy model, the charge pairs are located on either side of the disulfide crosslink (Fig. 5a). Although the Rosetta-Dock protocol does not emphasize electrostatics, the model suggests that, with modest rearrangement of side chain rotamers, these pairs of residues should be close enough to form favorable electrostatic interactions.

Alignment of the PA molecules from the energetically favorable model and its starting model reveals that LF<sub>N</sub> has shifted by a rmsd of 20 Å. This large departure from the starting model is because of a twist in LF<sub>N</sub> that unexpectedly minimizes the interaction of LF<sub>N</sub> with PA subsite II. As modeled, LF<sub>N</sub> contacts the K197 residue of the PA<sub>63</sub>-PA<sub>63</sub> interface but does not make any direct contacts with R178 and R200 (the two other residues of the second subsite suggested by the mutagenesis work done in the PA dimer; ref. 8) (Figs. 1b and 5c). We found that it was not possible to identify an alternate low-energy model in which LF<sub>N</sub> could interact with these residues. One possibility is that there is a conformational change in LF<sub>N</sub> and/or PA that could not be modeled by using rigid backbone structures. We now question, however, whether LF<sub>N</sub>-dependent dimerization of the oligomerization-deficient PA mutants yielded an unambiguous map of binding defects. Because R178, K197, and R200 are located at the dimer interface, it is possible that mutation of these residues causes oligomerization defects and does not directly affect ligand binding. Because PA dimers are formed only in the presence of ligand, it is difficult to distinguish these two possibilities. Given that the subsite II data may not reflect LF<sub>N</sub> binding and that the model recapitulates the independently identified disulfide and electrostatic pairs, we propose the low-energy model as a reliable prediction of the LF<sub>N</sub>-PA dimer complex structure. The fact that a purely energy-based prediction can reproduce the experimental results quite well and even point at possible incorrect information is encouraging and demonstrates that high-resolution structure prediction can make useful contributions to the structural characterization of a protein-protein interface, particularly in conjunction with experimental data. The combination of experimental and computational methods in this study may represent the beginning of a new paradigm for structure determination as computational methods become more accurate and structural biologists seek to understand larger and more complex systems that are less amenable to traditional high-resolution structure-determination methods.

The energetically favorable model has LF<sub>N</sub> spanning two neighboring PA<sub>63</sub> subunits with a buried surface area of 2,300 Å<sup>2</sup> (Fig. 5a and c). Although no experiments were conducted on the EF<sub>N</sub>-PA interaction for this study, the EF<sub>N</sub> structure aligns to

the LF<sub>N</sub> of the refined model with an rmsd of 1.7 Å<sup>2</sup> for 191 Cα atoms, suggesting that EF<sub>N</sub> and LF<sub>N</sub> bind PA similarly. By contrast, the LF<sub>N</sub>-binding site overlaps but is distinct from the PA<sub>20</sub>-binding sites. PA cannot oligomerize in the presence of PA<sub>20</sub> because of steric clash. The model shows that a single LF<sub>N</sub> molecule binds across two neighboring PA<sub>63</sub> subunits and displaces the PA<sub>20</sub> fragments of both subunits. This may explain why ligand binding is so important for PA oligomerization.

The bulk of the LF<sub>N</sub> interactions are nonetheless with a single PA<sub>63</sub> subunit. There is excellent packing between the PA-binding site on LF<sub>N</sub> (Fig. 1a) and the PA ligand-binding subsite I (Fig. 1b) with a significant number of electrostatic interactions (Fig. 5b). The interface also contains a buried His residue contributed by LF<sub>N</sub>, H229. The prevalence of charged residues at the interface may be relevant to the pH dependence of the subsequent steps of translocation. The low pH of the endosome triggers conversion of the PA heptameric prepore to the pore and initiates the process of ligand translocation. Low pH also seems to aid the unfolding of LF<sub>N</sub>, a process required to transport such a large molecule through the narrow pore lumen (10). Because the enzymatic ligand ultimately needs to be released from the heptamer surface to be translocated, there may be a pH dependence to the binding affinity as well. This pH dependence could be achieved by having a high number of charged and/or titratable residues at the interface.

An electrostatic interaction also may be involved in LF<sub>N</sub>'s contacts with the PA<sub>63</sub>-PA<sub>63</sub> interface, because the model indicates that LF<sub>N</sub> E135 and the K197 residue from the neighboring PA subunit will be in close proximity (Fig. 5a). An attempt to verify this interaction by pairing charge-reversal mutants was unsuccessful (data not shown) but may reflect the fact that PA K197 contributes to the binding interaction from both subunits (Fig. 1b). Despite the lack of direct contacts with R178 and R200 of subsite II, the model does suggest that LF<sub>N</sub> spans an interface and structurally occludes the neighboring subunit of PA (Fig. 5c). This occlusion is consistent with the observations that only three molecules of EF/LF/LF<sub>N</sub> can bind the heptamer at one time (7) and that the PA<sub>63</sub> dimer formed from two nonoligomerizing mutants binds only a single LF<sub>N</sub> molecule (16). Finally, the model indicates that the N-terminal α-helix of LF<sub>N</sub> is oriented over the luminal space of the PA heptamer (Fig. 5c and d). This helix, corresponding to residues 27-43, represents the first visible part of the LF<sub>N</sub> crystal structure, because the N-terminal 26 residues are presumably disordered (12). It has been shown that the N terminus initiates the translocation of LF<sub>N</sub> through the lumen of the PA heptameric pore (24). Having LF<sub>N</sub> bound such that the N-terminal helix is poised above this opening should facilitate this process and may mean that the N-terminal 26 residues can bind inside the prepore lumen before the beginning of pore formation and translocation (Fig. 5d).

This work was supported by a Charles A. King Trust postdoctoral fellowship (to D.B.L.) and National Institutes of Health Grant AI022021.

- Collier, R. J. & Young, J. A. (2003) *Annu. Rev. Cell Dev. Biol.* **19**, 45-70.
- Leppla, S. H. (1982) *Proc. Natl. Acad. Sci. USA* **79**, 3162-3166.
- Duesbery, N. S., Webb, C. P., Leppla, S. H., Gordon, V. M., Klimpel, K. R., Copeland, T. D., Ahn, N. G., Oskarsson, M. K., Fukasawa, K., Paull, K. D. & Vande Woude, G. F. (1998) *Science* **280**, 734-737.
- Vitale, G., Pellizzari, R., Recchi, C., Napolitani, G., Mock, M. & Montecucco, C. (1998) *Biochem. Biophys. Res. Commun.* **248**, 706-711.
- Molloy, S. S., Bresnahan, P. A., Leppla, S. H., Klimpel, K. R. & Thomas, G. (1992) *J. Biol. Chem.* **267**, 16396-16402.
- Milne, J. C., Furlong, D., Hanna, P. C., Wall, J. S. & Collier, R. J. (1994) *J. Biol. Chem.* **269**, 20607-20612.
- Mogridge, J., Cunningham, K. & Collier, R. J. (2002) *Biochemistry* **41**, 1079-1082.
- Cunningham, K., Lacy, D. B., Mogridge, J. & Collier, R. J. (2002) *Proc. Natl. Acad. Sci. USA* **99**, 7049-7053.
- Gordon, V. M., Leppla, S. H. & Hewlett, E. L. (1988) *Infect. Immun.* **56**, 1066-1069.
- Krantz, B. A., Trivedi, A. D., Cunningham, K., Christensen, K. A. & Collier, R. J. (2004) *J. Mol. Biol.* **344**, 739-756.
- Zhang, S., Udho, E., Wu, Z., Collier, R. J. & Finkelstein, A. (2004) *Biophys. J.* **87**, 3842-3849.
- Pannifer, A. D., Wong, T. Y., Schwarzenbacher, R., Renatus, M., Petosa, C., Bienkowska, J., Lacy, D. B., Collier, R. J., Park, S., Leppla, S. H., et al. (2001) *Nature* **414**, 229-233.
- Shen, Y., Zhukovskaya, N. L., Guo, Q., Florian, J. & Tang, W. J. (2005) *EMBO J.* **24**, 929-941.
- Elliott, J. L., Mogridge, J. & Collier, R. J. (2000) *Biochemistry* **39**, 6706-6713.
- Lacy, D. B., Mourez, M., Fouassier, A. & Collier, R. J. (2002) *J. Biol. Chem.* **277**, 3006-3010.

16. Mogridge, J., Cunningham, K., Lacy, D. B., Mourez, M. & Collier, R. J. (2002) *Proc. Natl. Acad. Sci. USA* **99**, 7045–7048.
17. Gray, J. J., Moughon, S., Wang, C., Schueler-Furman, O., Kuhlman, B., Rohl, C. A. & Baker, D. (2003) *J. Mol. Biol.* **331**, 281–299.
18. Schueler-Furman, O., Wang, C. & Baker, D. (2005) *Proteins* **60**, 187–194.
19. Benson, E. L., Huynh, P. D., Finkelstein, A. & Collier, R. J. (1998) *Biochemistry* **37**, 3941–3948.
20. Wigelsworth, D. J., Krantz, B. A., Christensen, K. A., Lacy, D. B., Juris, S. J. & Collier, R. J. (2004) *J. Biol. Chem.* **279**, 23349–23356.
21. Zhao, J., Milne, J. C. & Collier, R. J. (1995) *J. Biol. Chem.* **270**, 18626–18630.
22. Wesche, J., Elliott, J. L., Falnes, P. O., Olsnes, S. & Collier, R. J. (1998) *Biochemistry* **37**, 15737–15746.
23. Schueler-Furman, O., Wang, C., Bradley, P., Misura, K. & Baker, D., *Science*, in press.
24. Zhang, S., Finkelstein, A. & Collier, R. J. (2004) *Proc. Natl. Acad. Sci. USA* **101**, 16756–16761.
25. Lacy, D. B., Wigelsworth, D. J., Melnyk, R. A., Harrison, S. C. & Collier, R. J. (2004) *Proc. Natl. Acad. Sci. USA* **101**, 13147–13151.